Synedgen, Inc.
Synedgen is a company dedicated to developing first-in-class therapeutics that improve patient outcomes by promoting barrier function to repair mucosal injury, particularly in the gastrointestinal (GI) tract. Their lead asset, MIIST305, is an orally delivered therapeutic designed to repair GI mucosal injury, restore GI function, and reduce inflammation and damage. The company's mission is to protect, restore, and repair the body through targeted therapies, scalable GMP production, excellent safety profiles, and a strong IP position.
Industries
Nr. of Employees
small (1-50)
Synedgen, Inc.
Claremont, California, United States, North America
Patents
Methods for treatment or prevention of damage resulting from radiation, trauma or shock
US-11975018-B2
View DetailsMethods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
US-11786547-B2
View Details
Methods for treatment or prevention of damage resulting from radiation, trauma or shock
US-11975018-B2
View DetailsMethods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
US-11786547-B2
View DetailsProducts
Clinic‑ready orally delivered GI mucosal‑repair therapeutic
An orally administered therapeutic candidate designed to restore gastrointestinal mucosal function and reduce inflammation and tissue damage; presented as a clinic‑ready lead asset.
Glycomics-based discovery platform
Discovery platform leveraging glycomics to identify and develop therapeutic molecules that promote mucosal barrier repair and regeneration.
Clinic‑ready orally delivered GI mucosal‑repair therapeutic
An orally administered therapeutic candidate designed to restore gastrointestinal mucosal function and reduce inflammation and tissue damage; presented as a clinic‑ready lead asset.
Glycomics-based discovery platform
Discovery platform leveraging glycomics to identify and develop therapeutic molecules that promote mucosal barrier repair and regeneration.
Services
Preclinical efficacy and safety testing of therapeutic candidates in animal models to support progression toward clinic.
Production and scale-up of therapeutic candidates under GMP to support clinical supply.
Preclinical efficacy and safety testing of therapeutic candidates in animal models to support progression toward clinic.
Production and scale-up of therapeutic candidates under GMP to support clinical supply.
Expertise Areas
- Gastrointestinal disease therapeutics
- Mucosal barrier repair and regeneration
- Glycomics-based therapeutic discovery
- Preclinical efficacy testing in rodent models
Key Technologies
- Glycomics / glycan-based therapeutics
- Oral drug formulation
- Murine (rodent) preclinical disease models
- GMP manufacturing processes
News & Updates
Preclinical data demonstrating the efficacy of MIIST305 in mitigating GI injury in a mouse model.
Leadership update with the appointment of Dr. Laura Saward as CSO.
Funding award to support the development of MIIST305 as a radiation countermeasure.
No recent articles available
Preclinical Efficacy of MIIST305 in Mitigating GI Injury
Demonstrated in mouse models, showing potential for clinical application.
Funding Award for Radiation Countermeasure Development
Received $2.2 million JWMRP award to support development.
Preclinical data demonstrating the efficacy of MIIST305 in mitigating GI injury in a mouse model.
Leadership update with the appointment of Dr. Laura Saward as CSO.
Funding award to support the development of MIIST305 as a radiation countermeasure.
No recent articles available
Preclinical Efficacy of MIIST305 in Mitigating GI Injury
Demonstrated in mouse models, showing potential for clinical application.
Funding Award for Radiation Countermeasure Development
Received $2.2 million JWMRP award to support development.